Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Vorasidenib Is Potential First Targeted Therapy for Low-Grade Glioma

June 4th 2023

Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

FDA Awards Orphan Drug Status to INB-400 and INB-410 for Newly Diagnosed Glioblastoma

May 5th 2023

The gamma-delta T-cell therapies INB-400 and INB-410 have received orphan drug designations from the FDA for use as potential therapeutic options in patients with newly diagnosed glioblastoma.

Dr Doonan on the Evaluation of IRAK-4 Inhibition With Emavusertib in Metastatic Brain Melanoma

May 3rd 2023

Bently P. Doonan, MD, discusses the evaluation of targeted inhibition of IRAK-4 with emavusertib in the treatment of metastatic brain melanoma.

FDA Grants Fast Track Designation to ERAS-801 in EGFR-altered Glioblastoma

May 2nd 2023

The FDA has granted a fast track designation to ERAS-801 for the treatment of adult patients with glioblastoma harboring EGFR gene alterations.

Dr Blanco on Unmet Needs for Pediatric Patients With Relapsed Brain Tumors

April 28th 2023

Jezabel Rodriguez-Blanco, PhD, discusses unmet needs for pediatric patients with relapsed brain tumors, including the need for additional treatment approaches for these patients.

Molecular Analysis Needed to Guide Further Study of Olaparib Plus Ceralasertib in Pediatric Advanced Cancers

April 18th 2023

The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.

Dr Brastianos Breaks Down the Basics of Meningiomas

April 11th 2023

Priscilla K. Brastianos, MD, explains the differences between low-grade meningiomas and aggressive high-grade tumors.

Dr. Sadai on Signs and Symptoms of High-Grade Meningiomas

April 4th 2023

Nader Sanai, MD, discusses symptoms associated with high-grade meningiomas, a rare brain tumor.

Dr. Brastianos on Recent Data in High-Grade Meningiomas

April 4th 2023

Priscilla K. Brastianos, MD, reviews recent findings in high-grade meningiomas, including data generated in her laboratory.

Improved Understanding of Genomics Drives Excitement in High-Grade Meningiomas

March 31st 2023

At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population.

FDA Grants Orphan Drug Designation to FORE8394 for Primary Brain and CNS Malignancies

March 21st 2023

The FDA has granted an orphan drug designation to FORE8394 for the treatment of primary brain and central nervous system malignancies.

FDA Approves Dabrafenib Plus Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma

March 16th 2023

The FDA has approved dabrafenib with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

Vorasidenib Meets PFS End Point in IDH1/2-Mutant Low-Grade Glioma

March 14th 2023

Vorasidenib monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma.

Will Immunotherapy Become a Standard of Care for Glioblastoma?

March 10th 2023

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

Temferon Lands FDA Orphan Drug Status for Glioblastoma Multiforme

March 2nd 2023

The FDA has granted an orphan drug designation to Temferon for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Grants Orphan Drug Designation to BEA-17 for Glioblastoma

February 1st 2023

The FDA has granted an orphan drug designation to BEA-17 for the treatment of patients with glioblastoma.

Dr. Ahluwalia on the Evaluation of SurVaxM With Temozolomide in Newly Diagnosed Glioblastoma

January 10th 2023

Manmeet Singh Ahluwalia, MD, discusses the evaluation of SurVaxM in combination with oral temozolomide in patients with newly diagnosed glioblastoma.

FDA Grants Orphan Drug Designation to Azeliragon for Glioblastoma

January 10th 2023

The FDA has granted an orphan drug designation to azeliragon for the treatment of patients with glioblastoma.

Tovorafenib Elicits Responses in Recurrent or Progressive Pediatric Low-Grade Glioma

January 9th 2023

Tovorafenib monotherapy generated responses in patients with recurrent or progressive pediatric low-grade glioma.